Precision Biosensor Balance Sheet Health
Financial Health criteria checks 5/6
Precision Biosensor has a total shareholder equity of ₩32.0B and total debt of ₩18.4B, which brings its debt-to-equity ratio to 57.5%. Its total assets and total liabilities are ₩62.5B and ₩30.5B respectively.
Key information
57.5%
Debt to equity ratio
₩18.43b
Debt
Interest coverage ratio | n/a |
Cash | ₩6.52b |
Equity | ₩32.03b |
Total liabilities | ₩30.45b |
Total assets | ₩62.48b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A335810's short term assets (₩18.4B) exceed its short term liabilities (₩13.3B).
Long Term Liabilities: A335810's short term assets (₩18.4B) exceed its long term liabilities (₩17.1B).
Debt to Equity History and Analysis
Debt Level: A335810's net debt to equity ratio (37.2%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if A335810's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A335810 has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: A335810 is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.